Navigation Links
Cornerstone Therapeutics' David Price Named 2009 Chief Financial Officer of the Year by the Triangle Business Journal

CARY, N.C., July 20 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq CM: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing products primarily for the respiratory and related markets, announced today that David Price, Executive Vice President, Finance, and Chief Financial Officer, has been named Triangle Business Journal's CFO of the Year in the Small Public Business category. Award recipients were recognized at the inaugural Triangle Business Journal's CFO of the Year Awards Luncheon held in Cary on July 14, 2009.

"David is very deserving of this award and we congratulate him on this honor," said Cornerstone's President and CEO, Craig Collard. "Cornerstone has achieved tremendous growth in recent months and David has played a critical role in shaping the direction of the Company. He has displayed a level of commitment and financial leadership unmatched by most."

Mr. Price joined Cornerstone Therapeutics as Executive Vice President, Finance, and Chief Financial Officer, in September 2008, just prior to the completion of the reverse merger between Critical Therapeutics, Inc. and Cornerstone BioPharma, Inc., a transaction he helped facilitate as managing director at Jefferies & Company, Inc. In addition, Mr. Price was instrumental in finalizing Cornerstone's recently announced agreement with Chiesi Farmaceutici, SpA, a leading European pharmaceutical company headquartered in Parma, Italy, that resulted in a $70 million transaction and Cornerstone's receipt of an exclusive 10-year license for the U.S. commercial rights to Curosurf(R), the world leading treatment approved by the U.S. Food and Drug Administration for Respiratory Distress Syndrome in premature infants.

Mr. Price has more than 25 years of international experience working for leading accounting and investment firms, including Jefferies & Company, Bear, Stearns & Co. and Price Waterhouse, as well as with Cornerstone Therapeutics. He holds an Honors degree in Accounting and Financial Management from Lancaster University in Lancaster, UK. Mr. Price is a Qualified Charter Accountant and a member of the Institute of Chartered Accountants in England and Wales.

About Cornerstone Therapeutics

Cornerstone Therapeutics Inc. (Nasdaq CM: CRTX), headquartered in Cary, N.C., is a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets. The Company currently promotes multiple marketed products in the United States to respiratory-focused physicians and key retail pharmacies with its specialty sales force. The Company also has a late-stage clinical pipeline with five regulatory approval submissions targeted within the next three years. Key elements of the Company's strategy are to in-license or acquire rights to underpromoted, patent-protected, branded respiratory or related pharmaceutical products, or late-stage product candidates; implement life cycle management strategies to maximize the potential value and competitive position of the Company's currently marketed products, newly acquired products and product candidates that are currently in development; grow product revenue through the Company's specialty sales force which is focused on the respiratory and related markets; and maintain and strengthen the intellectual property position of the Company's currently marketed products, newly acquired products and product candidates.

Curosurf(R) is a registered trademark of Chiesi Farmaceutici, SpA.

SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product
2. Cornerstone Therapeutics Joins the Russell 3000(R) Index
3. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Issuance and Sale of Stock
4. TFAH Applauds Affordable Health Choices Act for Making Prevention a Cornerstone of Health Reform
5. Cornerstone Therapeutics Announces Management Change
6. Cornerstone Therapeutics Reports First Quarter 2009 Financial Results
7. Cornerstone Therapeutics Announces $70 Million Strategic Transaction With Chiesi Farmaceutici SpA
8. Cornerstone Therapeutics to Host First Quarter 2009 Conference Call
9. OnCore(r) 9.0 Released: 'Top 5' Priorities and Collaborative Initiatives Cornerstones of Product Development
10. Cornerstone Therapeutics Announces New Board of Directors
11. Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics
Post Your Comments:
(Date:11/27/2015)... ... November 28, 2015 , ... There is only one major question facing ... last year? , This question has not been an easy question to answer. Especially ... age and the younger workforce don’t share the same discipline around working long hours. ...
(Date:11/27/2015)... Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... study carried out by the University of Toronto and the University of British Columbia ... of hospitalizations for head injuries. The article explains that part of the reason for ...
(Date:11/27/2015)... ... November 27, 2015 , ... The ... in America. As people age, more care is needed, especially with Alzheimer’s, dementia ... medical professionals are being overworked. The forgotten part of this equation: 80 percent ...
(Date:11/27/2015)... ... November 27, 2015 , ... An inventor, ... to dispense prescription medications at home, so he invented the patent-pending ELECTRONIC M.D. ... dispense prescription medications. In doing so, it could help to prevent potential overdose ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... Lizzie’s ... , The company is offering customers 10% off of their purchase of lice treatment ... treatment at full price. According to a company spokesperson. “Finding lice is a sure ...
Breaking Medicine News(10 mins):
(Date:11/29/2015)... Nov. 29, 2015  The GE Health Cloud 1 ... Society of North America (RSNA) meeting ... healthcare industry, the new cloud ecosystem and its applications will ... care pathways and multidisciplinary teams – both inside and outside ... and CEO of GE. "As the digital industrial leader, we ...
(Date:11/27/2015)... 27, 2015 Une nouvelle ... au Bremachlorin contre le cancer avancé.    ... combiner l,immunothérapie au traitement photodynamique au Bremachlorin contre ... Une nouvelle approche consistant à combiner l,immunothérapie ... avancé.    Clinical Cancer Research ...
(Date:11/27/2015)... 2015  Lannett Company, Inc. (NYSE: LCI ... acquisition of Kremers Urban Pharmaceuticals Inc. (KU), the ... company UCB S.A. (Euronext: UCB). ... KU from UCB for total consideration of approximately ... customary working capital adjustment, a deduction of certain ...
Breaking Medicine Technology: